Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin

Journal of Lipid Research

Volumn 49, Issue 10, 2008, Pages 2142-2148

  Jaichander, Priscilla ^a   Selvarajano, Krithika ^a   Garelnabi, Mahdi ^a   Parthasarathy, Sampath ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Arylhydrocarbon receptor; Atherosclerosis; HDL; Paraoxon; Salicylate

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; ARYLHYDROCARBON RECEPTOR; RECEPTOR PROTEIN; SALICYLIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; APOLIPOPROTEIN A-I; ARYLDIALKYLPHOSPHATASE; ASPIRIN; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE SILENCING; HEPATOCYTES; HUMANS; MICE; RATS; RECEPTORS, ARYL HYDROCARBON; RNA, SMALL INTERFERING; SALICYLATES;

EID: 67649783977     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M800082-JLR200     Document Type: Article

References (34)

1. Teiber, J. F., D. I. Draganov, and B. N. La Du. 2004. Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH. J. Lipid Res. 45: 2260-2268.
2. Teiber, J. F., D. I. Draganov, and B. N. La Du. 2003. Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem. Pharmacol. 66: 887-896.
3. Jakubowski, H. 2000. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J. Biol. Chem. 275: 3957-3962.
4. Shamir, R., C. Hartman, R. Karry, E. Pavlotzky, R. Eliakim, J. Lachter, A. Suissa, and M. Aviram. 2005. Paraoxonases (PONs) 1, 2, and 3 are expressed in human and mouse gastrointestinal tract and in Caco-2 cell line: selective secretion of PON1 and PON2. Free Radic. Biol. Med. 39: 336-344.
5. Deakin, S., X. Moren, and R. W. James. 2007. HDL oxidation compromises its influence on paraoxonase-1 secretion and its capacity to modulate enzyme activity. Arterioscler Thromb Vasc Biol. 27: 1146-1152.
6. Aviram, M., M. Rosenblat, C. L. Bisgaier, R. S. Newton, S. L. Primo- Parmo, and B. N. La Du. 1998. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101: 1581-1590.
7. Karabina, S. A., A. N. Lehner, E. Frank, S. Parthasarathy, and N. Santanam. 2005. Oxidative inactivation of paraoxonase - implications in diabetes mellitus and atherosclerosis. Biochim. Biophys. Acta. 1725: 213-221.
8. Shih, D. M., L. Gu, Y. R. Xia, M. Navab, W. F. Li, S. Hama, L. W. Castellani, C. E. Furlong, L. G. Costa, A. M. Fogelman, et al. 1998. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 394: 284-287.
9. Tward, A., Y. R. Xia, X. P. Wang, Y. S. Shi, C. Park, L. W. Castellani, A. J. Lusis, and D. M. Shih. 2002. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 106: 484-490.
10. Ng, C. J., N. Bourquard, S. Y. Hama, D. Shih, V. R. Grijalva, M. Navab, A. M. Fogelman, and S. T. Reddy. 2007. Adenovirusmediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 27: 1368-1374.
11. Rader, D. J. 2002. High-density lipoproteins and atherosclerosis. Am. J. Cardiol. 90: 62-70.
12. Moore, R. E., M. Navab, J. S. Millar, F. Zimetti, S. Hama, G. H. Rothblat, and D. J. Rader. 2005. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ. Res. 97: 763-771.
13. Gusman, J., H. Malonne, and G. Atassi. 2001. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis. 22: 1111-1117.
14. Pervaiz, S. 2003. Resveratrol: from grapevines to mammalian biology. FASEB J. 17: 1975-1985.
15. Gouedard, C., R. Barouki, and Y. Morel. 2004. Dietary polyphenols increase paraoxonase 1 gene expression by an aryl hydrocarbon receptor-dependent mechanism. Mol. Cell. Biol. 24: 5209-5222.
16. Ciolino, H. P., P. J. Daschner, and G. C. Yeh. 1999. Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A-I transcription differentially. Biochem. J. 340: 715-722.
17. Vane, J. R., and R. M. Botting. 2003. The mechanism of action of aspirin. Thromb. Res. 110: 255-258.
18. Wu, K. K. 2003. Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin. Vasc. Med. 3: 107-112.
19. Vane, J. R. 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231: 232-235.
20. Breddin, H. K. 2004. Aspirin and platelet function. J. Thromb. Haemost. 2: 1216-1218.
21. Cyrus, T., Y. Yao, L. X. Tung, and D. Pratico. 2006. Stabilization of advanced atherosclerosis in low-density lipoprotein receptordeficient mice by aspirin. Atherosclerosis. 184: 8-14.
22. Fu, C. J., S. Melethil, and W. D. Mason. 1991. The pharmacokinetics of aspirin in rats and the effect of buffer. J. Pharmacokinet. Biopharm. 19: 157-173.
23. Petersen, T., S. E. Husted, A. K. Pedersen, and E. Geday. 1982. Systemic availability of acetylsalicylic acid in human subjects after oral ingestion of three different formulations. Acta Pharmacol. Toxicol. (Copenh.). 51: 285-291.
24. Santanam, N., and S. Parthasarathy. 2007. Aspirin is a substrate for paraoxonase-like activity: implications in atherosclerosis. Atherosclerosis. 191: 272-275.
25. Gouedard, C., N. Koum-Besson, R. Barouki, and Y. Morel. 2003. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Mol. Pharmacol. 63: 945-956.
26. Abbott, C. A., M. I. Mackness, S. Kumar, A. J. Boulton, and P. N. Durrington. 1995. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15: 1812-1818.
27. Januzzi, J. L., N. Azrolan, A. O'Connell, K. Aalto-Setala, and J. L. Breslow. 1992. Characterization of the mouse apolipoprotein Apoa-1/ Apoc-3 gene locus: genomic, mRNA, and protein sequences with comparisons to other species. Genomics. 14: 1081-1088.
28. Vu-Dac, N., S. Chopin-Delannoy, P. Gervois, E. Bonnelye, G. Martin, J. C. Fruchart, V. Laudet, and B. Staels. 1998. The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erb alpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J. Biol. Chem. 273: 25713-25720.
29. Rong, R., S. Ramachandran, M. Penumetcha, N. Khan, and S. Parthasarathy. 2002. Dietary oxidized fatty acids may enhance intestinal apolipoprotein A-I production. J. Lipid Res. 43: 557-564.
30. Kopp, E., and S. Ghosh. 1994. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 265: 956-959.
31. Mohan, W. S., Z. Q. Chen, X. Zhang, K. Kahlili, T. Honjo, R. G. Deeley, and S.P Tam. 1998. Human S mu binding protein-2 binds to the drug response element and transactivates the human apoA-I promoter: role of gemfibrozil. J. Lipid Res. 39: 255-267.
32. Fallone, F., P. H. Villard, L. Decome, E. Seree, M. Meo, C. Chacon, A. Durand, Y. Barra, and B. Lacarelle. 2005. PPAR alpha activation potentiates AhR-induced CYP1A-I expression. Toxicology. 216: 122-128.
33. Wallace, J. L., L. J. Ignarro, and S. Fiorucci. 2002. Potential cardioprotective actions of no-releasing aspirin. Nat. Rev. Drug Discov. 5: 375-382.
34. Blatter-Garin, M. C., B. Kalix, S. De Pree, and R. W. James. 2003. Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1. Diabetologia. 46: 593-594.